A Phase I Trial Adding Poly(ADP-ribose) Polymerase Inhibitor Veliparib to Induction Carboplatin-Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Alliance A091101
- Citation:
- Oral Oncol vol 114 105171
- Year:
- 2021
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Preliminary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 10
- Parents:
- 2900
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Experimental
- Sec. Committees:
- Pharmas:
- Abbvie
- Grants:
- U10CA180821, U10CA180882, UG1CA233327
- Corr. Author:
- Authors:
- Michael J. Jelinek Nathan R. Foster Alex J. Zoroufy Gary K. Schwartz Pamela N. Munster Tanguy Y. Seiwert Jonas A. de Souza Everett E. Vokes
- Networks:
- CA824, COLUMBIA, IL043, LAPS-IL057, LAPS-MD017, LAPS-MN026
- Study
- Alliance-A091101
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 1/2
- Keywords:
- Head and neck squamous cell carcinoma, induction therapy, veliparib, PARP inhibition